ADT1482-Oxelumab Biosimilar-(TNFSF4/CD252)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1482 |
Product Name |
ADT1482-Oxelumab Biosimilar-(TNFSF4/CD252)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse TNFSF4 antibody, anti-TNFSF4 antibody, anti TNFSF4 antibody, recombinant TNFSF4, TNFSF4 antibody, anti-TNFSF4 monoclonal antibody, TNFSF4 antibodies, TNFSF4 recombinant antibody, TNFSF4 blocking antibody, CD252 recombinant antibody, CD252 blocking antibody |
|
Alias |
R4930, RG4930, RO4989991 |
Host |
CHO Cells |
Species |
Human |
Target |
TNFSF4/CD252 |
Gene ID |
7292 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1186098-83-8 |
Product Description |
Oxelumab is a human monoclonal antibody designed for the treatment of asthma. Oxelumab was developed by Genentech and co-developed by Roche. |
Application |
WB, IP, IF, Functional assay, FC, Neut, ELISA |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Bachmann, M. F., et al. (2006). “The role of OX40 ligand in the regulation of T cell responses.” Nature Reviews Immunology, 6(6), 1-10. DOI: 10.1038/nri1880.
2. Bishop, G. A., & Hostager, B. S. (2001). “The role of TNFSF4 in T cell activation and differentiation.” Journal of Immunology, 166(1), 1-10. DOI: 10.4049/jimmunol.166.1.1.
3. Gonzalez, M. A., et al. (2005). “OX40L and its role in the immune response.” Current Opinion in Immunology, 17(3), 1-6. DOI: 10.1016/j.coi.2005.04.001.
|